Do analysts recommend NCNA or LPCN?

Lipocine has a consensus target price of $4.00, indicating a potential upside of 132.56%. Given Lipocine's stronger consensus rating and higher probable upside, analysts plainly believe Lipocine is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lipocine 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, NCNA or LPCN?

Lipocine has higher revenue and earnings than NuCana. Lipocine is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NuCana N/A N/A -$38.71M -$3.81 N/A Lipocine $1.98M 7.16 -$9.63M -$1.79 N/A

Is NCNA or LPCN more profitable?

NuCana has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. NuCana's return on equity of -41.90% beat Lipocine's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -41.90% -33.69% Lipocine -755.39% -64.75% -57.62%

Do analysts rate NCNA or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NCNA or ZIVO more profitable?

ZIVO Bioscience's return on equity of 0.00% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -41.90% -33.69% ZIVO Bioscience N/A N/A -2,240.92%

Do analysts prefer or NCNA?

Given 's higher possible upside, equities research analysts clearly believe is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, or NCNA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio N/A N/A N/A N/A N/A NuCana N/A N/A -$38.71M -$3.81 N/A

Is or NCNA more profitable?

's return on equity of 0.00% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets N/A N/A N/A NuCana N/A -41.90% -33.69%

Which has better earnings and valuation, ACTU or NCNA?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A NuCana N/A N/A -$38.71M -$3.81 N/A

Is ACTU or NCNA more profitable?

NuCana's return on equity of -41.90% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -346.19% -178.40% NuCana N/A -41.90% -33.69%

Do analysts recommend NCNA or DARE?

Dare Bioscience has a consensus price target of $6.50, indicating a potential upside of 740.44%. Given Dare Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Dare Bioscience is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is NCNA or DARE more profitable?

NuCana has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. NuCana's return on equity of -41.90% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -41.90% -33.69% Dare Bioscience -803.80% -748.30% -38.75%

NuCana (NCNA) Competitors

$1.10 -0.03 (-2.65%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.12 +0.02 (+2.00%)

As of 10/9/2026 07:50 PM Eastern

Compare

NCNA vs. LPCN, ZIVO, CYCN, ACTU, and DARE

Should you buy NuCana stock or one of its competitors? NuCana's main competitors and comparable companies include Lipocine (LPCN), ZIVO Bioscience (ZIVO), Cyclerion Therapeutics (CYCN), Actuate Therapeutics (ACTU), and Dare Bioscience (DARE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does NuCana compare to Lipocine?

NuCana (NASDAQ:NCNA) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

NuCana has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. NuCana's return on equity of -41.90% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-41.90%	-33.69%
Lipocine	-755.39%	-64.75%	-57.62%

NuCana has a beta of 2.3, meaning that its share price is 130% more volatile than the broader market. Comparatively, Lipocine has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

In the previous week, Lipocine had 12 more articles in the media than NuCana. MarketBeat recorded 13 mentions for Lipocine and 1 mentions for NuCana. Lipocine's average media sentiment score of 0.64 beat NuCana's score of 0.00 indicating that Lipocine is being referred to more favorably in the news media.

Company	Overall Sentiment
NuCana	Neutral
Lipocine	Positive

44.0% of NuCana shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 31.2% of NuCana shares are held by company insiders. Comparatively, 4.7% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lipocine has higher revenue and earnings than NuCana. Lipocine is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A
Lipocine	$1.98M	7.16	-$9.63M	-$1.79	N/A

Lipocine has a consensus target price of $4.00, indicating a potential upside of 132.56%. Given Lipocine's stronger consensus rating and higher probable upside, analysts plainly believe Lipocine is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lipocine beats NuCana on 8 of the 15 factors compared between the two stocks.

How does NuCana compare to ZIVO Bioscience?

NuCana (NASDAQ:NCNA) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

44.0% of NuCana shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 31.2% of NuCana shares are owned by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ZIVO Bioscience has higher revenue and earnings than NuCana. ZIVO Bioscience is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A
ZIVO Bioscience	$15.85K	1,409.43	-$7.78M	-$1.40	N/A

ZIVO Bioscience's return on equity of 0.00% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-41.90%	-33.69%
ZIVO Bioscience	N/A	N/A	-2,240.92%

NuCana has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

In the previous week, NuCana had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 1 mentions for NuCana and 0 mentions for ZIVO Bioscience. NuCana's average media sentiment score of 1.82 beat ZIVO Bioscience's score of 0.00 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
ZIVO Bioscience	Neutral

Summary

NuCana beats ZIVO Bioscience on 7 of the 12 factors compared between the two stocks.

How does NuCana compare to ?

(:) and NuCana (NASDAQ:NCNA) are related companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

's return on equity of 0.00% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
	N/A	N/A	N/A
NuCana	N/A	-41.90%	-33.69%

In the previous week, had 1220 more articles in the media than NuCana. MarketBeat recorded 1221 mentions for and 1 mentions for NuCana. NuCana's average media sentiment score of 1.82 beat 's score of 0.00 indicating that NuCana is being referred to more favorably in the news media.

Company	Overall Sentiment
	Neutral
NuCana	Very Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
	N/A	N/A	N/A	N/A	N/A
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A

Given 's higher possible upside, equities research analysts clearly believe is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

44.0% of NuCana shares are owned by institutional investors. 31.2% of NuCana shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

and NuCana tied by winning 4 of the 8 factors compared between the two stocks.

How does NuCana compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and NuCana (NASDAQ:NCNA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

44.0% of NuCana shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by insiders. Comparatively, 31.2% of NuCana shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Actuate Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A

In the previous week, Actuate Therapeutics had 2 more articles in the media than NuCana. MarketBeat recorded 3 mentions for Actuate Therapeutics and 1 mentions for NuCana. Actuate Therapeutics' average media sentiment score of 0.00 equaled NuCana'saverage media sentiment score.

Company	Overall Sentiment
Actuate Therapeutics	Neutral
NuCana	Neutral

Actuate Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, NuCana has a beta of 2.3, suggesting that its share price is 130% more volatile than the broader market.

Actuate Therapeutics presently has a consensus price target of $10.50, indicating a potential upside of 1,620.75%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Actuate Therapeutics is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NuCana's return on equity of -41.90% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-346.19%	-178.40%
NuCana	N/A	-41.90%	-33.69%

Summary

Actuate Therapeutics beats NuCana on 7 of the 12 factors compared between the two stocks.

How does NuCana compare to Dare Bioscience?

NuCana (NASDAQ:NCNA) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Dare Bioscience has higher revenue and earnings than NuCana. Dare Bioscience is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A
Dare Bioscience	$1.03M	14.77	-$13.40M	-$0.70	N/A

In the previous week, Dare Bioscience had 2 more articles in the media than NuCana. MarketBeat recorded 3 mentions for Dare Bioscience and 1 mentions for NuCana. NuCana's average media sentiment score of 1.82 beat Dare Bioscience's score of 0.40 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
Dare Bioscience	Neutral

NuCana has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. NuCana's return on equity of -41.90% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-41.90%	-33.69%
Dare Bioscience	-803.80%	-748.30%	-38.75%

NuCana has a beta of 2.3, meaning that its share price is 130% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

Dare Bioscience has a consensus price target of $6.50, indicating a potential upside of 740.44%. Given Dare Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Dare Bioscience is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

44.0% of NuCana shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Comparatively, 4.1% of Dare Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

NuCana beats Dare Bioscience on 8 of the 15 factors compared between the two stocks.

Get NuCana News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCNA vs. The Competition

Export

Metric	NuCana	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.70M	$12.29B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-0.29	797.58	275.30	26.16
Price / Sales	N/A	939.75	635.97	107.53
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	0.14	10.71	11.22	6.33
Net Income	-$38.71M	$2.84B	$3.50B	$382.15M
7 Day Performance	0.92%	-0.94%	-0.89%	-1.40%
1 Month Performance	-17.91%	-4.89%	-4.42%	-3.47%
1 Year Performance	-79.36%	-4.12%	7.03%	1.18%

NuCana Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCNA NuCana	1.3489 of 5 stars	$1.10 -2.7%	N/A	-81.5%	$4.70M	N/A	N/A	11	Positive News Gap Up
LPCN Lipocine	4.1642 of 5 stars	$1.93 -12.3%	$4.00 +107.3%	-45.4%	$18.14M	$1.98M	N/A	14	News Coverage Analyst Downgrade Gap Down
ZIVO ZIVO Bioscience	N/A	$4.24 +3.4%	N/A	-59.3%	$17.87M	$15.85K	N/A	10	Gap Up
CYCN Cyclerion Therapeutics	N/A	$3.49 +3.9%	N/A	N/A	$16.33M	$2.07M	N/A	30	Gap Up High Trading Volume
ACTU Actuate Therapeutics	2.2208 of 5 stars	$0.68 -6.2%	$10.50 +1,446.4%	-92.5%	$16.31M	N/A	N/A	12	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCNA) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NuCana (NCNA) Competitors

NCNA vs. LPCN, ZIVO, CYCN, ACTU, and DARE

How does NuCana compare to Lipocine?

Summary

How does NuCana compare to ZIVO Bioscience?

Summary

How does NuCana compare to ?

Summary

How does NuCana compare to Actuate Therapeutics?

Summary

How does NuCana compare to Dare Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NuCana (NCNA) Competitors

NCNA vs. LPCN, ZIVO, CYCN, ACTU, and DARE

How does NuCana compare to Lipocine?

Is NCNA or LPCN more profitable?

Which has more volatility and risk, NCNA or LPCN?

Does the media favor NCNA or LPCN?

Do insiders and institutionals have more ownership in NCNA or LPCN?

Which has better earnings & valuation, NCNA or LPCN?

Do analysts recommend NCNA or LPCN?

Summary

How does NuCana compare to ZIVO Bioscience?

Do insiders and institutionals believe in NCNA or ZIVO?

Do analysts rate NCNA or ZIVO?

Which has higher earnings and valuation, NCNA or ZIVO?

Is NCNA or ZIVO more profitable?

Which has more volatility and risk, NCNA or ZIVO?

Does the media prefer NCNA or ZIVO?

Summary

How does NuCana compare to ?

Is or NCNA more profitable?

Does the media refer more to or NCNA?

Which has stronger earnings and valuation, or NCNA?

Do analysts prefer or NCNA?

Do insiders & institutionals believe in or NCNA?

Summary

How does NuCana compare to Actuate Therapeutics?

Do insiders & institutionals believe in ACTU or NCNA?

Which has better earnings and valuation, ACTU or NCNA?

Does the media refer more to ACTU or NCNA?

Which has more risk & volatility, ACTU or NCNA?

Do analysts recommend ACTU or NCNA?

Is ACTU or NCNA more profitable?

Summary

How does NuCana compare to Dare Bioscience?

Which has better earnings & valuation, NCNA or DARE?

Does the media refer more to NCNA or DARE?

Is NCNA or DARE more profitable?

Which has more risk & volatility, NCNA or DARE?

Do analysts recommend NCNA or DARE?

Do insiders & institutionals believe in NCNA or DARE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools